549 related articles for article (PubMed ID: 28445659)
1. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis.
Ramanan AV; Dick AD; Jones AP; McKay A; Williamson PR; Compeyrot-Lacassagne S; Hardwick B; Hickey H; Hughes D; Woo P; Benton D; Edelsten C; Beresford MW;
N Engl J Med; 2017 Apr; 376(17):1637-1646. PubMed ID: 28445659
[TBL] [Abstract][Full Text] [Related]
2. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.
Ramanan AV; Dick AD; Jones AP; Hughes DA; McKay A; Rosala-Hallas A; Williamson PR; Hardwick B; Hickey H; Rainford N; Hickey G; Kolamunnage-Dona R; Culeddu G; Plumpton C; Wood E; Compeyrot-Lacassagne S; Woo P; Edelsten C; Beresford MW
Health Technol Assess; 2019 Apr; 23(15):1-140. PubMed ID: 31033434
[TBL] [Abstract][Full Text] [Related]
3. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial).
Ramanan AV; Dick AD; Benton D; Compeyrot-Lacassagne S; Dawoud D; Hardwick B; Hickey H; Hughes D; Jones A; Woo P; Edelsten C; Beresford MW;
Trials; 2014 Jan; 15():14. PubMed ID: 24405833
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness Analysis of Adalimumab for the Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis.
Hughes DA; Culeddu G; Plumpton CO; Wood E; Dick AD; Jones AP; McKay A; Williamson PR; Compeyrot Lacassagne S; Hardwick B; Hickey H; Woo P; Beresford MW; Ramanan AV
Ophthalmology; 2019 Mar; 126(3):415-424. PubMed ID: 30336181
[TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis-associated uveitis.
Renton WD; Jung J; Palestine AG
Cochrane Database Syst Rev; 2022 Oct; 10(10):CD013818. PubMed ID: 36239193
[TBL] [Abstract][Full Text] [Related]
6. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis.
Quartier P; Baptiste A; Despert V; Allain-Launay E; Koné-Paut I; Belot A; Kodjikian L; Monnet D; Weber M; Elie C; Bodaghi B;
Ann Rheum Dis; 2018 Jul; 77(7):1003-1011. PubMed ID: 29275333
[TBL] [Abstract][Full Text] [Related]
7. Anti-adalimumab antibodies kinetics: an early guide for juvenile idiopathic arthritis (JIA) switching.
Brunelli JB; Silva CA; Pasoto SG; Saa CGS; Kozu KT; Goldenstein-Schainberg C; Leon EP; Vendramini MBG; Fontoura N; Bonfa E; Aikawa NE
Clin Rheumatol; 2020 Feb; 39(2):515-521. PubMed ID: 31707543
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab in Juvenile Idiopathic Arthritis-Associated Uveitis: 5-Year Follow-up of the Bristol Participants of the SYCAMORE Trial.
Horton S; Jones AP; Guly CM; Hardwick B; Beresford MW; Lee RW; Dick AD; Ramanan AV
Am J Ophthalmol; 2019 Nov; 207():170-174. PubMed ID: 31201796
[TBL] [Abstract][Full Text] [Related]
9. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry.
Foeldvari I; Becker I; Horneff G
Arthritis Care Res (Hoboken); 2015 Nov; 67(11):1529-35. PubMed ID: 25988824
[TBL] [Abstract][Full Text] [Related]
10. Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis.
Cecchin V; Zannin ME; Ferrari D; Pontikaki I; Miserocchi E; Paroli MP; Bracaglia C; Marafon DP; Pastore S; Parentin F; Simonini G; De Libero C; Falcini F; Petaccia A; Filocamo G; De Marco R; La Torre F; Guerriero S; Martino S; Comacchio F; Muratore V; Martini G; Vittadello F; Zulian F
J Rheumatol; 2018 Aug; 45(8):1167-1172. PubMed ID: 29657140
[TBL] [Abstract][Full Text] [Related]
11. Risk Factors and Biomarkers for the Occurrence of Uveitis in Juvenile Idiopathic Arthritis: Data From the Inception Cohort of Newly Diagnosed Patients With Juvenile Idiopathic Arthritis Study.
Tappeiner C; Klotsche J; Sengler C; Niewerth M; Liedmann I; Walscheid K; Lavric M; Foell D; Minden K; Heiligenhaus A
Arthritis Rheumatol; 2018 Oct; 70(10):1685-1694. PubMed ID: 29732713
[TBL] [Abstract][Full Text] [Related]
12. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
Shepherd J; Cooper K; Harris P; Picot J; Rose M
Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate.
Lovell DJ; Brunner HI; Reiff AO; Jung L; Jarosova K; Němcová D; Mouy R; Sandborg C; Bohnsack JF; Elewaut D; Gabriel C; Higgins G; Kone-Paut I; Jones OY; Vargová V; Chalom E; Wouters C; Lagunes I; Song Y; Martini A; Ruperto N
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32665432
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of adalimumab in young children with juvenile idiopathic arthritis and chronic uveitis: a case series.
La Torre F; Cattalini M; Teruzzi B; Meini A; Moramarco F; Iannone F
BMC Res Notes; 2014 May; 7():316. PubMed ID: 24886032
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.
Lovell DJ; Ruperto N; Goodman S; Reiff A; Jung L; Jarosova K; Nemcova D; Mouy R; Sandborg C; Bohnsack J; Elewaut D; Foeldvari I; Gerloni V; Rovensky J; Minden K; Vehe RK; Weiner LW; Horneff G; Huppertz HI; Olson NY; Medich JR; Carcereri-De-Prati R; McIlraith MJ; Giannini EH; Martini A; ;
N Engl J Med; 2008 Aug; 359(8):810-20. PubMed ID: 18716298
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab for juvenile idiopathic arthritis-associated uveitis.
Magli A; Forte R; Navarro P; Russo G; Orlando F; Latanza L; Alessio M
Graefes Arch Clin Exp Ophthalmol; 2013 Jun; 251(6):1601-6. PubMed ID: 23446556
[TBL] [Abstract][Full Text] [Related]
17. Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results.
Brunner HI; Nanda K; Toth M; Foeldvari I; Bohnsack J; Milojevic D; Rabinovich CE; Kingsbury DJ; Marzan K; Chalom E; Horneff G; Kuester RM; Dare JA; Trachana M; Jung LK; Olson J; Minden K; Quartier P; Bereswill M; Kalabic J; Kupper H; Lovell DJ; Martini A; Ruperto N;
Arthritis Care Res (Hoboken); 2020 Oct; 72(10):1420-1430. PubMed ID: 31421019
[TBL] [Abstract][Full Text] [Related]
18. Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis.
Correll CK; Bullock DR; Cafferty RM; Vehe RK
Clin Rheumatol; 2018 Feb; 37(2):549-553. PubMed ID: 29103180
[TBL] [Abstract][Full Text] [Related]
19. Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis.
Smolen JS; Feist E; Fatenejad S; Grishin SA; Korneva EV; Nasonov EL; Samsonov MY; Fleischmann RM;
N Engl J Med; 2022 Aug; 387(8):715-726. PubMed ID: 36001712
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
